Source:http://linkedlifedata.com/resource/pubmed/id/16182177
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2005-9-26
|
| pubmed:abstractText |
We analyzed the outcomes of 24 consecutive patients aged >or=60 years with poor-prognosis myelodysplastic syndrome or acute myeloid leukemia undergoing transplantation with nonmyeloablative conditioning using fludarabine (125 mg/m2) and low-dose total body irradiation (2 Gy) followed by allogeneic peripheral blood stem cell grafts from HLA-identical sibling donors. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and mycophenolate mofetil. The median age of the patients was 64 years (range, 60-71 years). In addition to age, 88% of patients had 1 or more adverse biological features of the disease. With a median follow-up of 21 months, 12 patients are alive, 11 of whom are disease free. The probabilities of 2-year overall and progression-free survival were 52% and 44%, respectively. The cumulative probabilities of relapse and of acute and chronic GVHD were 27%, 45%, and 74%, respectively. Nonrelapse mortality at 100 days and 2 years was 8% and 25%, respectively. Of the 15 patients with extensive chronic GVHD, 1 patient relapsed. These data suggest that nonmyeloablative stem cell transplantation is a feasible treatment option in patients aged >or=60 years with poor-prognosis myelodysplastic syndrome or acute myeloid leukemia. The reasonable disease control with nonmyeloablative transplantation in this high-risk group of patients merits further investigation.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1083-8791
|
| pubmed:author |
pubmed-author:ChunKathyK,
pubmed-author:DalyAndrewA,
pubmed-author:GuptaVikasV,
pubmed-author:HasegawaWandaW,
pubmed-author:Kamel-ReidSuzanneS,
pubmed-author:KissThomasT,
pubmed-author:LiptonJeffrey HJH,
pubmed-author:MessnerHansH,
pubmed-author:MindenMarkM,
pubmed-author:TsangRichardR,
pubmed-author:YiQi-longQL
|
| pubmed:issnType |
Print
|
| pubmed:volume |
11
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
764-72
|
| pubmed:meshHeading |
pubmed-meshheading:16182177-Acute Disease,
pubmed-meshheading:16182177-Aged,
pubmed-meshheading:16182177-Female,
pubmed-meshheading:16182177-Graft Survival,
pubmed-meshheading:16182177-Graft vs Host Disease,
pubmed-meshheading:16182177-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:16182177-Histocompatibility Testing,
pubmed-meshheading:16182177-Humans,
pubmed-meshheading:16182177-Leukemia, Myeloid,
pubmed-meshheading:16182177-Male,
pubmed-meshheading:16182177-Middle Aged,
pubmed-meshheading:16182177-Myelodysplastic Syndromes,
pubmed-meshheading:16182177-Opportunistic Infections,
pubmed-meshheading:16182177-Siblings,
pubmed-meshheading:16182177-Survival Analysis,
pubmed-meshheading:16182177-Transplantation Conditioning,
pubmed-meshheading:16182177-Vidarabine,
pubmed-meshheading:16182177-Whole-Body Irradiation
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
|
| pubmed:affiliation |
Blood and Marrow Transplant Program, Princess Margaret Hospital, Toronto, Ontario, Canada. vikas.gupta@uhn.on.ca
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|